- Home
- SKYE vs MDCX Comparison
SKYE vs MDCX Comparison
Compare SKYE & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | MDCX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 23.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | MDCX |
|---|---|---|
| Price | $0.65 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.00 | $14.50 |
| AVG Volume (30 Days) | 122.6K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.25 |
| 52 Week High | $4.99 | $3.13 |
Technical Indicators
Market Signals| Indicator | SKYE | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 46.86 |
| Support Level | $0.57 | $0.28 |
| Resistance Level | $0.84 | $0.38 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 43.88 | 25.25 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.